Destiny Pharma plc is set to become the latest UK biotech to bid farewell to the London Stock Exchange’s Alternative Investment Market (AIM) and will take the private route to access cash for its late-stage pipeline and stave off liquidation.
Destiny Joins AIM Exodus In Bid To Stay Afloat
Chairman Sir Nigel Rudd said re-registering as a private company is necessary to provide Destiny Pharma with a realistic chance of securing the capital required to progress XF-73 Nasal through clinical trials, without which “liquidation of the company is the most likely alternative.”

More from Strategy
More from Business
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.